Laboratorios Bagó > Productos > Rosuvast 5 / 10 / 20 / 40

Rosuvast 5 / 10 / 20 / 40
Forma farmacéutica:
Comprimidos Recubiertos
Composición:
Cada comprimido recubierto contiene:
Rosuvast 5 mg: Rosuvastatina 5 mg
Rosuvast 10 mg: Rosuvastatina 10 mg
Rosuvast 20 mg: Rosuvastatina 20 mg
Rosuvast 40 mg: Rosuvastatina 40 mg
Acción Terapéutica:
Inhibidor de la HMG-CoA reductasa.
Indicaciones:
- Hiperlipidemia y dislipidemia mixta.
- Pacientes pediátricos de 10 a 17 años de edad con hipercolesterolemia familiar heterocigótica.
- Hipertrigliceridemia.
- Disbetalipoproteinemia primeria ( Hiperlipoproteinemia tipo III).
- Hipercolesterolemia familiar homocigota.
- Retraso de la progresión de la aterosclerosis.
- Prevención de eventos cardiovasculares.
Presentaciones:
Rosuvast 5 mg: Envases por 28, 30 y 60 comp. rec.
Rosuvast 10 mg: Envases por 28, 30, 56 y 60 comp. rec.
Rosuvast 20 mg:Envases por 28, 30 y 60 comp. rec.
Rosuvast 40 mg: Envases por 28 y 30 comp. rec.
- Hiperlipidemia y dislipidemia mixta.
- Pacientes pediátricos de 10 a 17 años de edad con hipercolesterolemia familiar heterocigótica.
- Hipertrigliceridemia.
- Disbetalipoproteinemia primeria ( Hiperlipoproteinemia tipo III).
- Hipercolesterolemia familiar homocigota.
- Retraso de la progresión de la aterosclerosis.
- Prevención de eventos cardiovasculares.
Presentaciones:
Rosuvast 5 mg: Envases por 28, 30 y 60 comp. rec. Rosuvast 10 mg: Envases por 28, 30, 56 y 60 comp. rec. Rosuvast 20 mg:Envases por 28, 30 y 60 comp. rec. Rosuvast 40 mg: Envases por 28 y 30 comp. rec. [post_title] => Rosuvast 5 / 10 / 20 / 40 [post_excerpt] => Inhibidor de la HMG-CoA reductasa. Código ATC: C10A A07. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => rosuvast [to_ping] => [pinged] => [post_modified] => 2022-11-22 12:25:17 [post_modified_gmt] => 2022-11-22 15:25:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.bago.com.ar/vademecum//?post_type=productos&p=1358 [menu_order] => 0 [post_type] => productos [post_mime_type] => [comment_count] => 0 [filter] => raw [prospecto_para_pacientes] => Array ( [0] => WP_Post Object ( [ID] => 19039 [post_author] => 17 [post_date] => 2021-07-14 09:52:12 [post_date_gmt] => 2021-07-14 12:52:12 [post_content] => [post_title] => ROSUVAST-informacion-para-el-paciente_ [post_excerpt] => [post_status] => inherit [comment_status] => open [ping_status] => closed [post_password] => [post_name] => rosuvast-informacion-para-el-paciente_-2 [to_ping] => [pinged] => [post_modified] => 2021-07-14 09:52:12 [post_modified_gmt] => 2021-07-14 12:52:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.bago.com.ar/vademecum/wp-content/uploads/2021/07/ROSUVAST-informacion-para-el-paciente_.pdf [menu_order] => 0 [post_type] => attachment [post_mime_type] => application/pdf [comment_count] => 0 [filter] => raw ) ) [url_para_mayor_informacion_video] => [url_para_mayor_informacion] => [url_productos_consumo_masivo] => [prospecto] => Array ( [0] => WP_Post Object ( [ID] => 19040 [post_author] => 17 [post_date] => 2021-07-14 09:53:10 [post_date_gmt] => 2021-07-14 12:53:10 [post_content] => [post_title] => ROSUVAST-prospecto [post_excerpt] => [post_status] => inherit [comment_status] => open [ping_status] => closed [post_password] => [post_name] => rosuvast-prospecto [to_ping] => [pinged] => [post_modified] => 2021-07-14 09:53:10 [post_modified_gmt] => 2021-07-14 12:53:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.bago.com.ar/vademecum/wp-content/uploads/2021/07/ROSUVAST-prospecto.pdf [menu_order] => 0 [post_type] => attachment [post_mime_type] => application/pdf [comment_count] => 0 [filter] => raw ) ) [presentacion_img] => Array ( ) [logo_img] => Array ( ) [foto_producto] => Array ( [0] => WP_Post Object ( [ID] => 2803 [post_author] => 16 [post_date] => 2012-07-26 19:14:10 [post_date_gmt] => 2012-07-26 19:14:10 [post_content] => [post_title] => img_rosuvast.jpg [post_excerpt] => [post_status] => inherit [comment_status] => open [ping_status] => open [post_password] => [post_name] => img_rosuvast-jpg [to_ping] => [pinged] => [post_modified] => 2012-07-26 19:14:10 [post_modified_gmt] => 2012-07-26 19:14:10 [post_content_filtered] => [post_parent] => 0 [guid] => [menu_order] => 0 [post_type] => attachment [post_mime_type] => image/jpeg [comment_count] => 0 [filter] => raw ) ) [fotos_lanzamiento] => Array ( ) [especialidad] => Array ( ) [marca] => Array ( [0] => Rosuvast ) [principio_activo] => Array ( [0] => Rosuvastatina ) [post_content_formatted] =>Forma farmacéutica:
Comprimidos Recubiertos
Composición:
Cada comprimido recubierto contiene:
Rosuvast 5 mg: Rosuvastatina 5 mg
Rosuvast 10 mg: Rosuvastatina 10 mg
Rosuvast 20 mg: Rosuvastatina 20 mg
Rosuvast 40 mg: Rosuvastatina 40 mg
Acción Terapéutica:
Inhibidor de la HMG-CoA reductasa.
Indicaciones:
- Hiperlipidemia y dislipidemia mixta.
- Pacientes pediátricos de 10 a 17 años de edad con hipercolesterolemia familiar heterocigótica.
- Hipertrigliceridemia.
- Disbetalipoproteinemia primeria ( Hiperlipoproteinemia tipo III).
- Hipercolesterolemia familiar homocigota.
- Retraso de la progresión de la aterosclerosis.
- Prevención de eventos cardiovasculares.
Presentaciones:
Rosuvast 5 mg: Envases por 28, 30 y 60 comp. rec.
Rosuvast 10 mg: Envases por 28, 30, 56 y 60 comp. rec.
Rosuvast 20 mg:Envases por 28, 30 y 60 comp. rec.
Rosuvast 40 mg: Envases por 28 y 30 comp. rec.
Información del producto: Rosuvast 5 / 10 / 20 / 40
Ver Prospecto > Ver Información para Pacientes >Bibliografía de Rosuvast 5 / 10 / 20 / 40
- Eficacia de la Rosuvastatina y de Dos Agentes Hipotensores en Personas con Riesgo Intermedio de Enfermedad Cardiovascular
- El Tratamiento con Estatinas en Niños Requiere Evaluación con Estudios a Largo Plazo
Publicaciones
- Guías Distinguidas Diabetología - Recomendaciones para el Tratamiento de la Diabetes
- Guías Distinguidas Diabetología - Diabetes Tipo 2